Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trialHaruhiro Saito, Makoto Maemondo, Yoshio Tsunezuka et al.|The Lancet Oncology|2019Cited by 636
Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancerTeppei Nishii, Munetaka Masuda, Tomoyuki Yokose et al.|BMC Cancer|2014Cited by 28
Prognostic value of <i>EGFR</i> mutations in surgically resected pathological stage I lung adenocarcinomaTeppei Nishii, Munetaka Masuda, Tomoyuki Yokose et al.|Asia-Pacific Journal of Clinical Oncology|2016Cited by 25